Skip to main content

Table 2 Course of sleep quality throughout the study

From: Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study

Patients Baseline visit 6-month visit 12-month visit 18-month visit 24-month visit
All patients, N 128 109 96 65 61
Patients with evaluable questionnaires, N 106 90 82 51 41
PSQI mean (SD) 7.31 (4.36) 6.37 (3.99) 6.43 (4.03) 6.45 (4.48) 6.71 (4.11)
PSQI median (range) 6.0 (1.0–18.0) 5.5 (1.0–20.0) 5.0 (1.0–18.0) 5.0 (0.0–18.0) 5.0 (1.0–18.0)
Proportion of patients with PSQI≥5 (95% confidence interval) 55.47 (46.43–64.25) 46.79 (37.17–56.59) 50.00 (39.62–60.38) 49.23 (36.60–61.93) 37.70 (25.61–51.04)
Sensitivity analysis, N 28 28 28 28 28
PSQI mean (SD) 6.75 (3.95) 6.43 (4.26) 6.00 (3.22) 6.21 (4.07) 6.29 (3.61)
PSQI median (range) 5.0 (1.0–14.0) 4.0 (1.0–18.0) 5.5 (2.0–14.0) 5.0 (1.0–18.0) 5.0 (1.0–16.0)
Proportion of patients with PSQI≥5 (95% confidence interval) 57.14 (37.18–75.54) 46.43 (27.51–66.13) 57.14 (37.18–75.54) 64.29 (44.07–81.36) 53.57 (33.87–72.49)
  1. PSQI Pittsburgh Sleep Quality Index, SD standard deviation